Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

导出 LinkOut

翻译打印收藏纠错

作者： Stephanie A,Nguyen ^[1] ; Owen D M,Stechishin ^[1] ; H Artee,Luchman ^[1] ; Xueqing Q,Lun ^[2] ; Donna L,Senger ^[2] ; Stephen M,Robbins ^[2] ; J Gregory,Cairncross ^[3] ; Samuel,Weiss ^[4]

作者单位： Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Cell Biology and Anatomy, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. ^[1] Clark Smith Brain Tumor Research Centre, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Oncology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. ^[2] Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Clark Smith Brain Tumor Research Centre, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. ^[3] Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Cell Biology and Anatomy, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Clark Smith Brain Tumor Research Centre, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. weiss@ucalgary.ca. ^[4]